Ahmedabad: Alembic Pharmaceuticals reported an 81% year-on-year rise in consolidated profit after tax (PAT) to Rs 335 crore for the Sept quarter of FY27. Revenue from operations climbed 36% to Rs 2,603 crore, compared with Rs 1,910 crore a year earlier.EBITDA surged 78% to Rs 578 crore during the quarter. The EBITDA margin stood at 22%. The US formulations business led the growth, with revenue jumping 77% to Rs 1,003 crore. The company launched three products in the US market during the quarter. Its ex-US business grew 12% to Rs 440 crore.Alembic’s India-branded business grew 14%, generating revenue of Rs 725 crore. Gynaecology, cardiology, gastroenterology and ophthalmology registered growth. Its animal health business grew 23%. The API business grew 39%, with revenue reaching Rs 436 crore.For the first half of FY27, consolidated revenue increased 31% to Rs 4,753 crore. US formulations revenue grew 64% to Rs 1,781 crore, while India branded revenue rose 10% to Rs 1,367 crore.Separately, Alembic expanded its strategic collaboration with US-based DifGen Pharmaceuticals to strengthen its complex generics portfolio in the American market.The collaboration covers more than 20 products across injectables, transdermal, ophthalmic and oral dosage forms. These address an aggregate reference market of about $5 billion. Initial product launches are expected from FY28.Under the arrangement, DifGen will lead product development, regulatory, manufacturing and supply activities. Alembic will manufacture select products and commercialise the portfolio in the US. The expanded partnership also provides Alembic access to manufacturing capacity at DifGen’s US facilities.
